2 results
Approved WMORecruiting
The primary objective of this study is to assess whether *omics technologies are sensitive and specific enough to be used as a chemical risk assessment tool for humans. More specifically the study will demonstrate if there are different and / or…
Approved WMORecruiting
Phase 1: • To determine the MTD/RP2D regimen of brigatinib monotherapy when administered in pediatric and AYA patients with ALK+ ALCL or ALK+ solid tumors, including ALK+ IMT.• To characterize the PK of brigatinib administered as monotherapy in…